dc.creator | Mandić, Danijela | |
dc.creator | Nežić, Lana | |
dc.creator | Amdžić, Ljiljana | |
dc.creator | Vojinović, Nataša | |
dc.creator | Gajanin, Radoslav | |
dc.creator | Popović, Miroslav | |
dc.creator | Đeri, Jugoslav | |
dc.creator | Todorović Balint, Milena | |
dc.creator | Dumanović, Jelena | |
dc.creator | Milovanović, Zoran | |
dc.creator | Grujić-Milanović, Jelica | |
dc.creator | Škrbić, Ranko | |
dc.creator | Jaćević, Vesna | |
dc.date.accessioned | 2023-09-12T08:45:35Z | |
dc.date.available | 2023-09-12T08:45:35Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2072-6694 | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/1343 | |
dc.description.abstract | Background: Approximately 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience treatment resistance to the first-line R-CHOP regimen. ATP binding cassette (ABC) transporters and survivin might play a role in multidrug resistance (MDR) in various tumors. The aim was to investigate if the coexpression of ABC transporters and survivin was associated with R-CHOP treatment response. Methods: The expression of Bcl-2, survivin, P-glycoprotein/ABCB1, MRP1/ABCC1, and BCRP/ABCC2 was analyzed using immunohistochemistry in tumor specimens obtained from patients with DLBCL, and classified according to the treatment response as Remission, Relapsed, and (primary) Refractory groups. All patients received R-CHOP or equivalent treatment. Results: Bcl-2 was in strong positive correlation with clinical parameters and all biomarkers except P-gp/ABCB1. The overexpression of MRP1/ABCC1, survivin, and BCRP/ABCC2 presented as high immunoreactive scores (IRSs) was detected in the Refractory and Relapsed groups (p < 0.05 vs. Remission), respectively, whereas the IRS of P-gp/ABCB1 was low. Significant correlations were found among either MRP1/ABCC1 and survivin or BCRP/ABCC2 in the Refractory and Relapsed groups, respectively. In multiple linear regression analysis, ECOG status along with MRP1/ABCC1 or survivin and BRCP/ABCG2 was significantly associated with the prediction of the R-CHOP treatment response. Conclusions: DLBCL might harbor certain molecular signatures such as MRP1/ABCC1, survivin, and BCRP/ABCC2 overexpression that can predict resistance to R-CHOP. | |
dc.language | en | |
dc.publisher | MDPI (Multidisciplinary Digital Publishing Institute) | |
dc.relation | COST (European Coopera-tion in Science and Technology) Action CA17104 STRATAGEM—“New diagnostic and therapeutictools against multidrug-resistant tumours” | |
dc.relation | Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, Serbia(MFVMA01/23–25) | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200015/RS// | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Cancers | |
dc.source | Cancers | |
dc.subject | BCRP/ABCC2 | |
dc.subject | MRP1/ABCC1 | |
dc.subject | multidrug resistance | |
dc.subject | non-Hodgkin lymphoma | |
dc.subject | survivin | |
dc.title | Overexpression of MRP1/ABCC1, Survivin and BCRP/ABCC2 Predicts the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Treatment | |
dc.type | article | en |
dc.rights.license | BY | |
dc.citation.issue | 16 | |
dc.citation.spage | 4106 | |
dc.citation.volume | 15 | |
dc.identifier.doi | 10.3390/cancers15164106 | |
dc.identifier.fulltext | http://rimi.imi.bg.ac.rs/bitstream/id/3081/Overexpression_of_MRP1ABCC1_Survivin_and_BCRPABCC2_pub_2023.pdf | |
dc.type.version | publishedVersion | |